Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SM 06

Next Previous
Drug Profile

SM 06

Alternative Names: SM-06

Latest Information Update: 04 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SinoMab Bioscience Ltd
  • Class Anti-inflammatories; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuromyelitis optica; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 23 Nov 2023 Sinimab BioSciences has patent protection for 'Anti-CD22 anti-idiotypic antibodies and uses' in USA
  • 23 Nov 2023 Preclinical trials in Neuromyelitis optica in USA, China (Parenteral) prior to November 2023 (SinoMab Bioscience pipeline, November 2023)
  • 23 Nov 2023 Preclinical trials in Rheumatoid arthritis in China, USA (Parenteral) prior to November 2023 (SinoMab Bioscience pipeline, November 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top